Clinical Trial Update: A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD) [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing patient preference between Spiriva Respimat and Spiriva Handihaler for COPD has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• SPIRIVA HANDIHALER (TIOTROPIUM BROMIDE)
• SPIRIVA RESPIMAT (tiotropium bromide inhalation spray)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 4 | Status: COMPLETED | Results posted: 2023-10-13